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Abstract: Development of contrast-induced nephropathy (CIN), ie, a rise in serum creatinine 
by either $0.5 mg/dL or by $25% from baseline within the first 2–3 days after contrast 
administration, is strongly associated with both increased inhospital and late morbidity and 
mortality after invasive cardiac procedures. The prevention of CIN is critical if long-term 
outcomes are to be optimized after percutaneous coronary intervention. The prevalence of 
CIN in patients receiving contrast varies markedly (from ,1% to 50%), depending on the 
presence of well characterized risk factors, the most important of which are baseline chronic 
renal insufficiency and diabetes mellitus. Other risk factors include advanced age, anemia, 
left ventricular dysfunction, dehydration, hypotension, renal transplant, low serum albumin, 
concomitant use of nephrotoxins, and the volume of contrast agent. The pathophysiology of CIN 
is likely to be multifactorial, including direct cytotoxicity, apoptosis, disturbances in intrarenal 
hemodynamics, and immune mechanisms. Few strategies have been shown to be effective to 
prevent CIN beyond hydration, the goal of which is to establish brisk diuresis prior to contrast 
administration, and to avoid hypotension. New strategies of controlled hydration and diuresis 
are promising. Studies are mixed on whether prophylactic oral N-acetylcysteine reduces the 
incidence of CIN, although its use is generally recommended, given its low cost and favorable 
side effect profile. Agents which have been shown to be ineffective or harmful, or for which 
data supporting routine use do not exist, include fenoldopam, theophylline, dopamine, calcium 
channel blockers, prostaglandin E1, atrial natriuretic peptide, statins, and angiotensin-converting 
enzyme inhibitors.
Keywords: contrast-induced nephropathy, contrast media, acute kidney injury, percutaneous 
coronary intervention
Introduction
Iodinated contrast agents are being widely utilized for diagnostic and therapeutic 
purposes. More than 1.2 million cardiac catheterizations are conducted in the US 
annually.1,2 The continuing growth of coronary interventions coupled with an aging 
population and increasing procedural complexity has resulted in an increased incidence 
of renal impairment caused by exposure to contrast agents, a disorder known as 
contrast-induced nephropathy (CIN).3
Definition and incidence
Definition of CIN is based on three essential components, ie, deterioration of renal 
function compared with baseline status, a temporal relationship between decline in 
renal function and exposure to a contrast agent, and ruling out alternative explanations International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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for renal impairment. For many years, due to ease and low 
cost, assessment of serum creatinine has been a mainstay to 
characterize renal function, and until recently, the majority 
of clinical studies used change in serum creatinine to define 
CIN. Although the definition of CIN varies across the trials, 
the most commonly used one includes an absolute increase 
in serum creatinine of $0.5 mg/dL (44.2 µmol/L) or a $25% 
relative increase in serum creatinine from the baseline value 
at 48–72 hours after exposure to contrast agent in the absence 
of alternative causes for acute kidney injury.4,5
The lack of a uniform definition of CIN led to   diversity 
in the incidence of CIN reported in the peer-reviewed 
  literature. According to the information on contrast media 
use available from the US Food and Drug Administration, the 
incidence of renal failure after contrast administration, based 
on serum creatinine criteria, ranged from 0.6% to 2.3%.6 
However, rates of CIN may be as high as 50%, depending 
on the   presence of well characterized risk factors, the most 
important of which are baseline chronic renal insufficiency 
and diabetes mellitus.3,4,7–10
However, serum creatinine is not an ideal marker of 
kidney function, for several reasons. First, serum creatinine 
undergoes tubular secretion into the urinary space. Second, 
levels of serum creatinine can vary widely depending on a 
large number of nonrenal factors including but not limited 
to age, gender, muscle mass, and hydration status. Third, 
serum creatinine is a relatively late marker of kidney injury, 
and up to 50% of kidney function may be lost before serum 
creatinine rises. Furthermore, serum creatinine does not 
accurately depict kidney function until steady state has been 
achieved (up to 2–3 days after injury) and is altered by renal 
replacement therapies. And last, but not least, depending on 
the method of measurement, several substances and drugs 
(eg, ketones, plasma proteins, and cephalosporins) are 
known to interfere with laboratory measurements of serum 
creatinine.11–15
Given the aforementioned drawbacks of serum creatinine 
as a measure of renal function injury, there is a call for more 
sensitive definitions of CIN to be included as a primary 
outcome in randomized clinical trials of CIN prevention. 
The role of several novel biomarkers is currently being 
investigated in patients experiencing acute kidney injury, 
including CIN.
Cystatin C, a protein member of the cysteine proteinase 
inhibitor family, is produced at a relatively constant rate by 
nucleated cells, is freely filtered at the glomerulus, and is 
then reabsorbed and metabolized by the proximal tubule.16 
In several settings, including contrast media exposure, 
cystatin C has been suggested as a sensitive marker of 
acute kidney injury.17 Compared with serum creatinine, the 
serum concentration of cystatin C is less dependent on age, 
gender, muscle mass, and nutrition, and therefore more reli-
ably predicts deterioration of renal function.18–20 Still, serum 
cystatin C levels do appear to be altered by several factors 
other than renal function, including thyroid dysfunction and 
glucocorticoid therapy.21–23
In a study by Briguori et al in 410 patients with pre-
existing renal dysfunction (estimated glomerular filtration 
rate ,60 mL/min/1.73 m2) undergoing coronary and/or 
peripheral procedures using contrast media, a serum cystatin 
C increase of $10% from baseline at 24 hours postprocedure 
was the best increment cutoff value for early identification of 
patients at increased risk of CIN.24 In the same study, a serum 
cystatin C increase of $10% was an independent predictor 
of all-cause mortality or requirement for permanent dialysis 
at one year.24 Likewise, in the post hoc analysis of the CARE 
(Cardiac Angiography in Renally Impaired Patients) study, 
development of CIN after contrast exposure, defined by 
changes in serum cystatin C of 15%, 20%, and 25% compared 
with baseline, was associated with an increased incidence of 
adverse events at one year.25
Neutrophil gelatinase-associated lipocalin (NGAL), 
a member of the lipocalin family, has been recognized to 
accumulate in the human kidney cortical tubules, blood, and 
urine after nephrotoxic and ischemic injuries, prompting 
its evaluation as a biomarker of acute renal injury.26,27 In a 
small series of 25 nondiabetic patients, with normal baseline 
serum creatinine and undergoing coronary angiography, a 
significant rise in both serum and urine NGAL and serum 
cystatin C was detected several hours after the procedure, 
with a return to baseline values within 48 hours, while 
levels of serum creatinine and creatinine clearance remained 
unchanged after the procedure.28 Another study of NGAL as a 
marker of renal function after elective cardiac catheterization 
and angiography in 91 children with congenital heart 
disease showed that NGAL allows early (within two 
hours after   contrast exposure) diagnosis of renal injury.29 
However, given that the level of NGAL may be increased 
in several inflammatory conditions, the place of NGAL as 
a marker of kidney injury needs to be determined further in 
future trials.30
Other markers of kidney injury have potential use 
in diagnosis of CIN. Kidney injury molecule is a type 1 
transmembrane adhesion protein, the expression of which 
is upregulated in the proximal tubule cells in response to 
ischemia. A soluble form can be detected in the urine of International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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both animal models and in patients suffering from acute 
kidney injury due to CIN.31,32 In patients undergoing coronary 
angiography, elevated levels of urinary alpha glutathione 
S-transferase were detected after exposure to contrast media, 
in the absence of changes in serum creatinine.33
Pathogenesis
The pathogenesis of CIN is still uncertain and is likely to be 
multifactorial. Contrast-induced renal injury is thought to 
depend on the formation of free radicals, generated within the 
acidic environment of the renal medulla. The hyperosmolar 
stress that accompanies the use of some contrast agents 
was shown to trigger prompt cellular generation of reactive 
oxygen species resulting in direct cytotoxicity and apoptosis 
of renal tubular and glomerular cells.34–36
The influence of contrast media on renal hemodynamics 
may also play a major role in the pathogenesis of CIN. 
The outer medulla is an area at risk for acute kidney injury 
given the vulnerability of this region to a decrease in oxygen 
tension. Several animal studies have documented contrast 
media-related constriction of the vasa recta supplying the 
outer medulla, and a decrease in renal medullary blood 
flow, glomerular filtration rate, red blood cell velocity, and 
oxygen tension, along with an increase in red blood cell 
aggregation.37–43 In another animal study, the intra-arterial 
administration of contrast media caused a biphasic response, 
with a short period of renal hyperperfusion followed by 
vasoconstriction with subsequent hypoperfusion and, finally, 
restoration of normal flow within several minutes.44 The vis-
cosity of contrast media has been shown to play a differential 
role in renal hemodynamics.45
In patients with chronic kidney disease (serum 
creatinine .1.5 mg/dL), administration of contrast medium 
during coronary intervention resulted in a gradual decline 
in renal blood flow velocity compared with the baseline 
level.46,47 In another small study of 14 patients with chronic 
renal insufficiency receiving an intravenous bolus of either 
high osmolar contrast diatrizoate or low osmolar contrast 
iopamidol, there was an immediate and progressive decline 
of both renal blood flow and glomerular filtration rate.48
The level of endothelin, a strong endogenous vasocon-
strictor, was found to be increased after exposure to contrast 
media, and is believed to be involved in the pathogenesis of 
CIN.49,50 Immunological mechanisms have been implicated 
as well.49,51
Atheroembolic renal disease, also known as atheroembo-
lism, may also contribute to deterioration of renal function 
after angiographic procedures, and should be considered in 
the differential diagnosis of acute renal failure after contrast 
exposure.52
Risk factors
Several major risk factors for the development of CIN 
have been identified, including baseline chronic renal 
insufficiency, diabetes mellitus, advanced age, anemia, 
congestive heart failure, impaired left ventricular systolic 
function, higher volume of contrast media, procedures 
  performed in the setting of hemodynamic instability, and 
the use of drugs with nephrotoxic properties close to contrast 
media exposure (Table 1).3,4,7,8,53–60
Chronic renal insufficiency
Preprocedural renal function impairment is the strongest 
predictor for CIN.3,4,7,10,58,61–63 The higher the baseline serum 
creatinine value, the greater the risk of CIN.4,58 Patients with 
preprocedural substantial renal function impairment have 
a more than tenfold increased risk of developing CIN than 
patients with normal or near normal preprocedural renal 
function.63–66
Diabetes mellitus
In diabetics with preserved renal function and no other risk 
factors, the rates of CIN are usually moderately increased 
or even comparable with those of the healthy population. 
Table 1 Factors associated with development of contrast-induced 
nephropathy
Nonmodifiable Modifiable
Patient-related factors
Advanced age Anemia
Diabetes mellitus Intravascular volume depletion
Preexisting chronic kidney  
disease with/without chronic  
renal insufficiency
Concomitant use of nephrotoxic  
agents/drugsa
Congestive heart failure Hypoalbuminemia (,3.5 g/dL)
Low cardiac output Periprocedural systemic hypotension/ 
hemodynamic instability
Renal transplant
Procedure-related factors
PCI performed in ACS setting High volume of contrast media
emergent intervention High-osmolality and ionicity of  
contrast media
Multiple administration of contrast  
media within 72 hours
Intra-aortic balloon pump
PCI-related blood loss
Note:  aNonsteroidal  anti-inflammatory  drugs,  cyclosporine,  aminoglycosides, 
cisplatinum.
Abbreviations:  PCI,  percutaneous  coronary  intervention; ACS,  acute  coronary 
syndrome.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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  However, diabetic patients with preprocedural renal 
impairment have a substantially increased risk of CIN and 
need for renal replacement therapy.7,10,67–69
Older age
Older age is strongly associated with CIN. Patients older 
than 75 years have an almost twofold increase in risk of CIN 
compared with younger patients.56 Age-related decrease in 
glomerular filtration rate, tubular secretion, and concentrating 
ability, and a higher prevalence of chronic kidney disease, 
anemia, and congestive heart failure, contribute to the 
increased incidence of CIN in the elderly.
Anemia and blood loss
Anemia is an independent predictor of CIN.56 Lower baseline 
hematocrit increases the risk of CIN for any given estimated 
glomerular filtration rate level, and patients combining 
both low baseline hematocrit and low estimated glomerular 
filtration rate are at the highest risk of developing CIN 
(Figure 1). The rates of CIN increase also with an incremental 
periprocedural drop in hematocrit.59
volume of contrast agent
Deterioration of renal function after contrast exposure 
  correlates closely with the volume of contrast media, the 
only modifiable risk factor for CIN. Still, a broad range of 
contrast volume (from ,100 mL to .800 mL) may increase 
the risk of CIN, depending mainly on patient characteristics, 
clinical scenarios, and CIN definition.3,4,7,8,53,56–58,61,67,69–74 
In one trial, the cutoff dose of contrast below which there 
were no cases of acute renal failure requiring dialysis after 
coronary intervention was 100 mL.3 However, in patients 
with both chronic renal insufficiency and diabetes mellitus, 
even less than 100 mL of contrast agent may cause CIN.69 
As shown in several series, the ratio of contrast volume to 
baseline estimated glomerular filtration rate may be a stronger 
predictor of CIN than contrast volume alone.75–78,79
Properties of contrast media
Iodine-containing agents are classified by their iodine 
content (quantity of iodine per mL of solution), osmolarity 
(hyperosmolar versus low osmolar versus iso-osmolar), level 
of ionization (ionic versus nonionic), viscosity, and degree 
of polymerization (monomeric versus dimeric, see Table 2). 
The properties of contrast media contribute to the incidence 
of CIN. Several randomized clinical trials have assessed 
the impact of contrast media osmolarity on the incidence 
of CIN. In patients with preexisting renal impairment, ionic 
high osmolar contrast media caused a higher degree of 
renal injury compared with nonionic low osmolar contrast 
media.67,80–82 However, there has been ongoing debate as to 
whether iso-osmolar contrast media provides benefit over 
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Table 2 Properties of contrast media
Generic  
name
Trade name Polymerization Osmolarity  
category
Osmolality  
(mOsm/kg H20)
Ionicity Iodine content  
(mg/ml)
Viscosity 
(cP@37°)
Diatrizoate Renografin®-76 Monomeric High osmolar 1,940 Ionic 370 9.1
Ioxaglate Hexabrix® Dimeric Low osmolar 600 Ionic 320 7.5
Iohexol Omnipaque® Monomeric Low osmolar 844 Nonionic 350 10.4
Iopamidol Isovue® Monomeric Low osmolar 796 Nonionic 370 9.4
Ioversol Opitray® Monomeric Low osmolar 702 Nonionic 320 5.8
Iopromide Ultravist® Monomeric Low osmolar 774 Nonionic 370 9.5
Iobitridol Xenetix® Monomeric Low osmolar 915 Nonionic 350 10.0
Iomeprol Iomeron® Monomeric Low osmolar 618 Nonionic 350 7.0
Iodixanol visipaque® Dimeric Iso-osmolar 290 Nonionic 320 11.8
low osmolar contrast media in terms of renal protection 
in patients undergoing contrast media exposure. The data 
from several comparative trials have yielded inconsistent 
results. In the NEPHRIC (Nephrotoxicity in High-Risk 
Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic 
Contrast Media) study performed in 129 patients with dia-
betes and baseline renal insufficiency undergoing cardiac 
and aortofemoral angiography, the nonionic isotonic dimer, 
iodixanol-320 (osmolality 290 mOsm/kg H2O), was associ-
ated with lower rates of CIN than the nonionic low osmolar 
monomer, iohexol-350 (osmolality 780 mOsm/kg H2O).83 
Similarly, in 300 patients with serum creatinine #60 mL/min 
in the RECOVER (Renal Toxicity Evaluation and Com-
parison between Visipaque and Hexabrix in Patients with 
Renal Insufficiency Undergoing Coronary Angiography) 
study, iodixanol was significantly less nephrotoxic than 
the ionic dimer low osmolar contrast ioxaglate (osmolality 
600 mOsm/kg H2O).84 However, this was not confirmed in a 
larger prospective, randomized trial comparing low osmolar 
contrast iodixanol with low osmolar contrast iopamidol in 
526 patients with diabetes mellitus and impaired baseline kid-
ney function undergoing coronary angiographic procedures.85 
Both the median peak in serum creatinine and the rates of 
CIN did not differ between the two study groups.85 Likewise, 
in the prospective randomized CARE trial, the rates of CIN, 
defined by multiple endpoints, were not different after intra-
arterial administration of low osmolar contrast iopamidol 
(osmolality 796 mOsm/kg H2O) or iodixanol in patients with 
moderate to severe chronic kidney disease.5 Furthermore, 
in the randomized ICON (Ionic versus Non-ionic Contrast 
to Obviate Worsening Nephropathy after Angioplasty in 
Chronic Renal Failure Patients) study performed in high-risk 
patients undergoing coronary angiographic procedures, use of 
nonionic low osmolar contrast iodixanol did not reduce renal 
deterioration in patients with renal impairment compared 
with ionic low osmolar contrast ioxaglate.86
The possible role for viscosity of contrast media in the 
pathogenesis of CIN was assessed in an animal model in 
which effects on renal hemodynamics of iopromide were 
compared with iodixanol, a contrast agent with relatively high 
viscosity and low osmolality.45 While both types of contrast 
media transiently increased renal blood flow, administration 
of contrast agent with higher viscosity was associated with 
decreased renal medullary blood flux, erythrocyte concentra-
tion, and pO2 content.
Readministration of contrast media
Certain clinical scenarios require repeat exposure to contrast 
media within a short time, increasing the risk of CIN. While 
there are no studies on the ideal timing for repeat contrast 
exposure, the time frame of 3 weeks seems reasonable given 
that, in the majority of CIN cases, renal function restores 
within this period.87
Combination of several risk factors
Patients undergoing contrast exposure have marked variation 
in CIN risk due to a combination of two or more risk factors. 
The risk of development of CIN following percutaneous 
coronary intervention has been shown to rise remarkably with 
the number of risk factors pres  ent. A simple risk score based 
on eight baseline measures identifies patients at increased 
risk for CIN/dialysis and subsequent one-year mortality, for 
whom rigorous preventive strategies should be implemented 
(Table 3).56,88
Serum creatinine trajectory after 
contrast exposure
Typically contrast media causes renal dysfunction within the 
first 12–24 hours, and serum creatinine reaches a peak at three 
days after contrast exposure. Patients with a ,0.5 mg/dL 
rise in serum creatinine within the first 24 hours of contrast 
exposure are unlikely to develop CIN.66International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
90
Sudarsky and Nikolsky
In most cases, the decline in renal function is mild and 
transient, with recovery of renal function starting within 
3–5 days. After 1–3 weeks, serum creatinine usually returns 
to the baseline value or resumes a new baseline level.7,89 
However, some patients have a persistent decline in renal 
function and subsequently require renal replacement therapy. 
As mentioned previously, this is most likely to occur in 
patients with preexisting renal dysfunction and/or multiple 
CIN risk factors.7,69,87,90
Implications of contrast-induced 
nephropathy
The development of CIN after diagnostic coronary angiog-
raphy and/or percutaneous interventions is associated 
with prolonged hospitalization, a marked increase in 
morbidity, inhospital mortality, and costs.3,4,25,53,57,58,61–63 
  Development of CIN also correlates with late morbidity and 
mortality.3,4,25,53,61,63
Contrast-induced nephropathy is the third most   common 
cause of acute renal failure in hospitalized patients.91 Nearly 
all cases of CIN reflect mild transient impairment of renal 
function, with dialysis needed in a small proportion of 
patients.87 However, in selected high-risk subgroups of 
patients, such as those with preexisting renal failure or 
diabetes, up to 7% require temporary dialysis or progress to 
end-stage renal disease.3,4,58,61,63 Once temporary dialysis is 
initiated, 13%–50% of patients will require permanent renal 
replacement therapy.3,61 Inhospital mortality is extremely high 
in patients requiring dialysis after percutaneous intervention 
(37% in a study by McCullough et al3 and 39% in the study 
by Freeman et al58).
Prevention
Given the negative prognostic impact of CIN, every attempt 
should be made to reduce its occurrence. The best approach to 
prevent CIN is to identify at-risk patients, provide adequate 
periprocedural hydration, and minimize the amount of 
  contrast administered. Multiple preventive measures have 
been evaluated, with very few of them being efficient in 
reducing CIN rates (Table 4).
Hydration
Adequate periprocedural hydration is a key component of 
preservation of renal function in patients undergoing contrast 
media exposure. The goal of hydration is maintenance of 
sufficient intravascular volume to increase renal perfusion, 
establishment of adequate diuresis prior to contrast media 
administration, and avoidance of hypotension.
The positive effect of adequate hydration in reducing 
rates of CIN was first established in a randomized study 
by   Solomon et al. Among 78 patients with chronic renal 
Table 4 Strategies evaluated for contrast-induced nephropathy 
risk reduction
Preventive strategies Efficacy
Pharmacologic strategies
Hydration Beneficial
Sodium bicarbonate Inconsistent data
Furosemide May be harmful
Mannitol May be harmful
N-acetylcysteine Inconsistent data
Dopamine No benefit
Fenoldopam No benefit
Theophylline/aminophylline Inconsistent data
Calcium channel blockers Inconsistent data
ACe inhibitor/angiotensin receptor blocker Inconsistent data
Atrial natriuretic peptide No benefit
Prostaglandin e1 May be beneficial
Statins May be beneficial
Nonpharmacologic strategies
Hemodialysis Inconsistent data
Hemofiltration May be beneficial
Benephit™ infusion system May be beneficial
RenalGuard® system May be beneficial
Abbreviation: ACe, angiotensin-converting enzyme.
Table 3 Risk prediction score for the development of contrast-
induced nephropathy and renal failure requiring dialysis35
Risk factors Integer score
Hypotensiona 5 points
Use of intra-aortic balloon pump 5 points
Congestive heart failureb 5 points
Age .75 years 4 points
Anemiac 3 points
Diabetes mellitus 3 points
volume of contrast media 1 point for each 100 mL
SCr . 1.5 mg/dL 4 points
or
eGFRd , 60 mL/min/1.73 m2 2 points for 40–60
4 points for 20–40
6 points for ,20
Risk assessment
Risk score Risk of CIN Risk of dialysis
,5 points 7.5% 0.04%
6–10 points 14% 0.12%
11–16 points 26.1% 1.09%
.16 points 57.3% 12.6%
Notes:  aHypotension: systolic blood pressure ,80 mmHg for at least one hour 
requiring inotropic support with medications or intra-aortic balloon pump within 
24 hours periprocedurally; bcongestive heart failure (New York Heart Association 
functional  class  III/Iv  and/or  history  of  pulmonary  edema);  canemia  (baseline 
hematocrit value ,39% for men and ,36% for women); deGFR (mL/min/1.73 m2) = 
186.3 × (sCrCIN)-1.154 × (age)-0.203 × (0.742 if female) × (1.210 if African-American).
Abbreviations: eGFR, estimated glomerular filtration rate; CIN, contrast-induced 
nephropathy; SCr, serum creatinine.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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insufficiency undergoing angiography, hydration with 
0.45% saline (1 mL/kg/hour for 12 hours preprocedure and 
postprocedure, n = 28 patients) provided better protection 
against renal function deterioration than hydration with 0.45% 
saline plus mannitol (n = 25 patients) or furosemide (n = 25 
patients, P = 0.02 for saline versus saline plus furosemide 
group).92 Several subsequent studies examined the optimal 
mode, timing, duration, and intensity of hydration.83,92–96
Mode of hydration
There is no consensus on the best mode of hydration to 
prevent CIN. In a small study of 36 patients and a larger 
study of 312 patients with mild-to-moderate renal failure, oral 
and intravenous fluid administration had similar protective 
effects against CIN.95,97 On the other hand, in the randomized 
study by Trivedi et al of 53 patients, CIN developed almost 
10-fold more frequently in patients who received oral versus 
intravenous hydration (34.6% versus 3.7%, P = 0.005).93 
Finally, in a retrospective analysis by Clavijo et al, rapid 
intra-arterial administration of 1000 mL of 5% dextrose 
immediately before catheterization was associated with 
a lower rate of CIN compared with standard intravenous 
hydration (1.4% versus 5.7%, respectively, P = 0.03).98
Isotonic saline versus half-isotonic saline
In a study by Mueller et al, intravenous administration of 
isotonic saline was found to be superior, compared with 
half-isotonic saline, in reducing the rates of CIN after 
percutaneous coronary intervention (0.7% versus 2%, 
respectively, P = 0.04). In a subgroup analysis, isotonic 
hydration was especially beneficial in women (0.6% versus 
5.1%), patients with diabetes mellitus (0% versus 5.5%) and 
patients receiving high ($250 mL) volumes of contrast.96
Continuous versus bolus hydration
In the randomized OTHER CAN (Optimal Timing of 
Hydration to Erase Contrast-Associated Nephropathy) study 
performed in 63 patients with moderate renal insufficiency 
undergoing elective cardiac catheterization, CIN rates tended 
to be lower (P = 0.14) in the group receiving overnight intra-
venous hydration compared with the group receiving bolus 
hydration.99 In another small study of 39 patients with pre-
procedural normal renal function undergoing an angiographic 
procedure randomized to receive either 300 mL of normal 
saline for the duration of contrast exposure or at least 2000 mL 
normal saline intravenously 12 hours before and after   contrast 
media administration, CIN occurred significantly more 
  frequently in patients who received bolus hydration.100
Regimens in specific patient populations
There is no uniform standard to guide hydration in patients 
undergoing contrast exposure, and the practice varies across 
the institutions. However, it is important to bear in mind that 
certain clinical scenarios, namely the presence of reduced 
left ventricular function and chronic renal insufficiency, 
require cautious fluid administration. One of the commonly 
recommended hydration regimens is 1 cc/kg/hour of normal 
saline for 12 hours before and after angiography for patients 
with normal ejection fraction; for patients with moderately or 
severely reduced ejection fraction, a recommended hydration 
practice includes volume replacement matching the urine 
output to maintain euvolemic state for 12 hours preprocedure 
and postprocedure. According to European guidelines for 
myocardial revascularization, all patients with chronic kidney 
disease undergoing diagnostic catheterization should receive 
preventive intravenous hydration with isotonic saline, to be 
started at least 12 hours before angiography and continued 
for at least 24 hours afterwards, in order to reduce the risk 
of CIN.101 The amount of contrast media delivered in these 
patients should not exceed 4 mL/kg.101
Use of sodium bicarbonate
Alkalinizing of the urine by sodium bicarbonate is thought 
to reduce contrast-induced renal injury by reducing the 
amount of pH-dependent free radicals. Several studies have 
been conducted to assess the efficacy of sodium bicarbonate 
in reduction of CIN rates, and provided conflicting results. 
In three prospective, randomized studies, preventive hydra-
tion with sodium bicarbonate provided better protection 
against CIN than an alternative hydration regimen.102–104 
However, in the largest randomized trial, by Brar et al, includ-
ing 353 patients with baseline estimated glomerular filtration 
rate #60 mL/min/1.73 m2, and at least one risk factor for CIN 
(diabetes, hypertension, history of chronic heart failure, or 
age older than 75 years), hydration with sodium bicarbonate 
provided no benefit.105 Moreover, in a large retrospective 
multivariate analysis from the Mayo Clinic, treatment with 
sodium bicarbonate was associated with an increased CIN 
risk (odds ratio 3.10, P , 0.001).106
Forced diuresis
Intensive hydration combined with a diuretic (forced diuresis) 
is aimed at creating and maintaining a high urine output, 
allowing rapid elimination of contrast agent and reducing 
its toxic effects.107 Several studies assessing the efficacy 
of forced diuresis to prevent CIN have yielded conflicting 
results. In a small, previously mentioned, randomized study International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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by Solomon et al, hydration with half-isotonic saline was 
superior to hydration with half-isotonic saline plus mannitol 
or hydration with half-isotonic saline plus furosemide.92 In the 
randomized PRINCE (Prevention of Radiocontrast Induced 
Nephropathy Clinical Evaluation) study in 98 patients, forced 
diuresis using intravenous crystalloid, furosemide, mannitol, 
and low-dose dopamine was compared with intravenous 
crystalloid hydration alone.108 Intravenous fluid replacement 
was performed, with the volume matching the urine output. 
According to the study results, despite a higher urine flow rate 
over the 24 hours after contrast exposure in the group treated 
with forced diuresis compared with the group that received 
routine hydration, there was only a modest benefit in reduc-
tion of CIN in favor of forced diuresis. Yet, in a subgroup of 
patients with urine flow rates .150 mL/hour postprocedure 
from the forced diuresis group, the CIN incidence was more 
than two times lower compared with patients who received 
routine hydration (21.6% versus 45.9%, P = 0.03). Note-
worthy is that matching fluid intake and urine output in the 
PRINCE study started only after contrast agent exposure. 
Thus, the patients might have had a depleted intravascular 
volume for the duration of time prior to the start of matched 
fluid replacement.108
In a small trial by Weinstein et al in 18 patients, the 
  addition of furosemide to intravenous hydration prior to sys-
temic exposure to contrast media caused significant deteriora-
tion of renal function, while no change occurred in the group 
  receiving hydration alone.109 Finally, in a study by Dussol et al 
in 312 patients with chronic renal insufficiency (mean esti-
mated glomerular filtration rate 37 mL/min/1.73 m2) exposed 
to contrast media, the addition of furosemide to intravenous 
hydration did not confer any additional benefit.97
The concept of forced diuresis to prevent CIN in high-
risk patients with chronic renal insufficiency has been 
further developed in studies assessing a novel automatic 
RenalGuard® system (PLC Systems Inc, Franklin, MA) 
to provide controlled hydration. The system is designed 
to measure urine output and to replace it with an equal 
volume of intravenous saline solution. Such matched fluid 
replacement aims at maintaining an individual intravascular 
fluid volume and minimizing the risk of either overhydration 
or underhydration. The randomized MYTHOS (Induced 
Diuresis With Matched Hydration Therapy Compared to 
Standard Overnight Hydration in the Prevention of Contrast 
Induced Nephropathy) trial evaluated the effectiveness of this 
controlled hydration system in reduction of CIN rates in 135 
patients with baseline renal insufficiency (estimated glomeru-
lar filtration rate ,60 mL/min/1.73 m2) undergoing elective 
or urgent percutaneous coronary intervention, assigned to 
forced diuresis using automated matched hydration therapy 
provided by the system or standard overnight hydration 
(1 mL/kg/hour preprocedure and postprocedure).110 The con-
trolled hydration protocol provided by the system included 
matched fluid replacement started approximately 90 minutes 
before, and was maintained during the procedure and up to 
four hours following percutaneous coronary intervention, and 
an initial bolus of 250 mL of normal saline over 30 minutes 
followed by intravenous bolus of furosemide 0.5 mg/kg 
when .300 mL/hour urine output was obtained. The use of 
the system was associated with a trend towards lower rates 
of CIN (6% versus 17%, P = 0.06) and a significantly lower 
incidence of inhospital major adverse cardiac events (6% 
versus 24% respectively, P = 0.008).110
The same hydration protocol using the controlled 
hydration system as that used in the MYTHOS study is 
currently being further assessed in the randomized open-
label REMEDIAL II (Renal Insufficiency Following Contrast 
Media Administration II Trial) trial in approximately 270 
patients with advanced renal insufficiency (baseline estimated 
glomerular filtration rate #30 mL/min/1.73 m2 or high 
baseline [$11] CIN risk score56) scheduled for coronary or 
peripheral angiography with or without angioplasty.111 The 
control group includes patients who receive intravenous 
hydration with sodium bicarbonate along with oral 
administration of N-acetyl-cysteine. 
Pharmacologic agents  
for prevention of CIN
N-acetylcysteine
There have been multiple studies and meta-analyses 
assessing the ability of the thiol-containing antioxidant, 
N-acetylcysteine, to prevent CIN. In the first randomized 
placebo-controlled study, by Tepel et al in 83 patients 
exposed to contrast media, prophylactic oral administration 
of N-acetylcysteine along with hydration was superior to 
hydration alone in preventing CIN in patients with elevated 
baseline serum creatinine levels, with rates of 2% in the 
N-acetylcysteine group compared with 21% in controls.112 
The subsequent APART (Acetylcysteine to Prevent 
Angiography-related Renal Tissue injury) trial, including 
54 patients and using a similar design, confirmed that CIN 
occurred in 8% of patients in the oral N-acetylcysteine group 
versus 45% in the placebo group.113 However, several other 
studies did not support the efficacy of N-acetylcysteine in 
preventing CIN. In a randomized study by Briguori et al in 
183 patients, oral N-acetylcysteine plus hydration failed to International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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show a significant difference in CIN rates compared with 
hydration alone.114 In another randomized study by Webb 
et al in 487 patients with impaired renal function, intravenous 
N-acetylcysteine was ineffective in preventing CIN.115 
Likewise, in the prospective, single-blinded, randomized 
LIPSIA-N-ACC (Leipzig Immediate PercutaneouS Coronary 
Intervention Acute Myocardial Infarction N-ACC) trial in 
251 patients undergoing primary angioplasty for ST-segment 
elevation myocardial infarction, high-dose intravenous 
N-acetylcysteine (1200 mg twice daily for 48 hours) did not 
reduced rates of CIN compared with placebo (14% versus 
20%, respectively, P = 0.28).116 Finally, the large, multicenter 
randomized, placebo-controlled ACT (Acetylcysteine 
for Contrast Induced Nephropathy) trial, reported at the 
2010 American Heart Association scientific sessions, failed 
to demonstrate a protective role for N-acetylcysteine in 
CIN reduction.117 This study included 2308 patients with 
at least one CIN risk factor (age .70 years, chronic renal 
insufficiency, diabetes mellitus, congestive heart failure, 
left ventricular ejection fraction #45%, or shock) from 
46 hospitals across Brazil. Patients were randomized to 
receive either oral N-acetylcysteine 1200 mg twice daily, 
with two doses given before the procedure and two doses 
given after the procedure, or to placebo. The primary 
endpoint, defined as $25% elevation of serum creatinine 
above baseline 48–96 hours after angiography, occurred in 
12.7% of patients in both groups (P = 0.97). Rates of other 
endpoints, including serum creatinine elevation .0.5 mg/dL 
(N-acetylcysteine 3.9% versus placebo 3.8%, P = 0.85) and 
doubling in serum creatinine compared with baseline value 
(1.1% versus 1.5%, respectively, P = 0.41) were also similar 
between the groups.
An important observation on the apparent lack of efficacy 
of N-acetylcysteine in prevention of CIN has been provided 
in the prospective study by Hoffmann et al in 50 healthy 
volunteers with normal renal function.118 In this study, the 
volunteers received N-acetylcysteine (four oral doses of 
600 mg every 12 hours) in the absence of administration of 
contrast media. According to the results, four hours after the 
last dose of N-acetylcysteine, there was a small but significant 
decrease in mean serum creatinine and urea concentrations 
and a significant increase in estimated glomerular filtration 
rate. However, levels of cystatin C remained unchanged 
after N-acetylcysteine administration. Given that cystatin C 
is a more reliable marker of deterioration of renal function, 
the authors concluded that creatinine metabolism is likely 
to be affected by N-acetylcysteine, questioning the role of 
N-acetylcysteine in prevention of CIN.118
Dopamine
Decreased renal blood flow due to vasoconstriction has been 
suggested as a contributory factor to the development of CIN. 
Given that low-dose dopamine has a dilatory effect on the 
renal vasculature, it may potentially have a renoprotective 
effect. However, dopamine failed to show a protective effect 
on renal function in patients undergoing contrast media 
exposure, and was even associated with a deleterious effect 
on the severity of renal failure and its duration.119,120
Fenoldopam
Fenoldopam is a selective, dopamine-1 receptor agonist 
that augments renal plasma flow. In a pilot trial, patients 
suffering from chronic renal failure (baseline serum 
creatinine 2.5–5.0 mg/dL) and undergoing angiography, were 
randomized to a combination of fenoldopam and hydration 
or hydration alone. The administration of fenoldopam 
resulted in an increase in renal plasma flow, a decrease 
in peak serum creatinine level 72 hours after exposure to 
contrast, and a trend towards a decreased incidence of CIN 
(21% and 41%, respectively, P = 0.14).121 However, in the 
multicenter, randomized CONTRAST (fenoldopam mesylate 
for the prevention of contrast-induced nephropathy) trial 
of 315 patients undergoing invasive cardiac procedures 
with an estimated creatinine clearance ,60 mL/min 
treatment with fenoldopam (0.05 µg/kg/min, titrated up to 
0.10 µg/kg/min) starting one hour before catheterization 
and continuing for 12 hours after, versus matching placebo, 
did not reduce the rate of CIN (33.6% versus 30.1%).122 
No subgroup was identified that demonstrated even a trend 
toward benefit with fenoldopam.
Theophylline and aminophylline
Adenosine, a renal vasoconstrictor, has been proposed to 
interfere with renal function and development of CIN by 
attenuation of renal blood flow and decrease in glomerular 
filtration perfusion pressure. Theophylline and aminophylline 
are nonspecific adenosine (A1) receptor antagonists that 
may lessen the decrease in renal blood flow and glomerular 
filtration rate induced by exposure to contrast medium.123 
  Several randomized studies have assessed the possible 
  protective role of theophylline on preservation of renal 
function in patients undergoing contrast exposure. In a 
randomized study by Huber et al, prophylactic intravenous 
administration of theophylline 200 mg reduced the 
incidence of CIN in 100 patients at risk, as compared with 
placebo (4% versus 16%, P = 0.046).124 However, in other 
randomized studies, administration of theophylline did not International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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provide any benefit in reduction of CIN rates compared with 
placebo.120,125,126 The results of two published meta-analyses 
seem to be inconclusive, due to significant heterogeneity in 
results across individual studies.127,128
Calcium channel blockers
The proposed mechanisms by which calcium antagonists 
may ameliorate renal damage following exposure to contrast 
media include favorable effects on renal hemodynamics 
(reversal of renal vasoconstriction), block of intracellular 
calcium overload induced by various types of ischemic or 
toxic stimuli, reduction in renal hypertrophy, modulation of 
mesangial traffic of macromolecules, and reduction of free 
radical formation.129 Several clinical studies investigated 
the effect of calcium channel blockers on rates of CIN and 
provided inconsistent results. In a small, randomized, placebo-
controlled study of 35 patients, estimated glomerular filtration 
rate was preserved in patients treated with nitrendipine but 
decreased in patients that received placebo.130 By contrast, in 
three other studies, the change in serum creatinine level did 
not differ significantly with calcium antagonists.131–133
ACI inhibitors and angiotensin  
receptor blockers
Given that the ACE inhibitors and angiotensin receptor 
blockers attenuate afferent arteriolar vasoconstriction,134,135 it 
has been hypothesized that their administration may reduce 
medullary ischemia and rates of CIN in patients undergoing 
contrast exposure. The role of the ACE inhibitor, captopril, in 
the prevention of CIN was prospectively investigated in a small 
randomized (albeit not placebo-controlled) study of 71 patients 
with diabetes mellitus undergoing coronary angiography.136 
Captopril was given at a dose of 25 mg three times daily 
for three days starting one hour prior to angiography. The 
glomerular filtration rate increased in the captopril group and 
decreased in the control group in this study. The increase in 
creatinine and blood urea nitrogen in the captopril group was 
significantly less prominent than in the control group. This 
was accompanied by 79% lower rates of CIN in the captopril-
treated group compared with the control group.136 However, 
these results were not supported by a retrospective study in 
230 patients 65 years of age or older, with baseline renal 
insufficiency and undergoing coronary angiography, in which 
the use of an ACE inhibitor was associated with an almost 
three-fold increase in rates of CIN.137 Given this controversy, 
it cannot currently be concluded that ACE inhibitors are effec-
tive in the prevention of CIN in patients at risk. Moreover, 
some investigators believe that ACE inhibitor/angiotensin 
receptor blocker therapy should be discontinued prior to con-
trast exposure. Yet, in a randomized prospective study of 220 
patients with advanced chronic kidney disease (glomerular 
filtration rate 15–60 mL/min/1.73 m2) receiving chronic treat-
ment with an ACE inhibitor or angiotensin receptor blocker, 
periprocedural (24 hours prior to and three days after coronary 
angiography) discontinuation of ACE inhibitor/angiotensin 
receptor blocker therapy did not confer any protective effect 
on kidney function or the incidence of CIN.138
Hence, there is not enough evidence as yet to support 
either the administration or withdrawal of ACE inhibitors 
or angiotensin receptor blockers prior to contrast exposure 
in patients at risk of CIN.
Atrial natriuretic peptide
Atrial natriuretic peptide in three different doses failed to 
prevent CIN in the randomized, placebo-controlled study 
by Kurnik et al.139
Prostaglandin e1
Based on the finding that patients with CIN have decreased 
levels of prostaglandins, causing a shift in physiologic 
vasoconstriction/vasodilatation balance, it was hypothesized 
that prophylactic administration of prostaglandin E1 might 
be beneficial in reducing rates of CIN.140 A double-blind, 
randomized, placebo-controlled study investigated the effect 
of intravenous administration of prostaglandin E1 at three 
different doses. All the groups treated with prostaglandin E1, 
independently of the given dose, experienced significantly 
less increase in serum creatinine compared with the placebo 
group after exposure to contrast media. The most pronounced 
effect was observed in patients who received the intermediate 
dose of the drug (20 ng/kg/minute).140
Statins
In two retrospective series of patients undergoing cardiac 
catheterization, pretreatment with statins was associated with 
lower rates of CIN.141,142 However, this was not confirmed in 
a prospective, randomized, double-blind, placebo-controlled, 
two-center trial of 247 consecutive patients with chronic renal 
insufficiency (calculated creatinine clearance #60 mL/min 
and/or serum creatinine $1.1 mg/dL) undergoing coronary 
angiography. Patients randomized to 160 mg simvastatin 
(40 mg orally every 12 hours starting the evening before 
and ending the morning after the procedure) versus   placebo 
had a similar mean peak increase in serum creatinine at 
48 hours after coronary angiography, rates of CIN, and 
clinical outcomes at one and 6 months.143International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Renal replacement therapy  
in prevention of contrast-induced 
nephropathy
Hemodialysis
Iodinated contrast agents are readily dialyzable. The plasma 
clearance of most modern contrast media is 50–70 mL/
min, with more than 80% removed from the plasma within 
4–5 hours of hemodialysis.144 Several studies have examined 
the effect of hemodialysis in preventing renal function dete-
rioration after exposure to contrast media, in patients with 
preexisting chronic kidney disease, providing inconsistent 
results. In two studies, prophylactic hemodialysis, imme-
diately after exposure to contrast media, failed to diminish 
the rates of CIN or complications.145,146 However, in another 
study, patients were randomized to intravenous hydration 
alone or hydration plus prophylactic hemodialysis following 
the procedure. Prophylactic hemodialysis was associated 
with a less prominent decrease in creatinine clearance within 
72 hours of contrast exposure and lower rates of need for 
subsequent temporary renal replacement therapy or need for 
long-term dialysis after discharge.147
Hemofiltration
In a prospective, single-center study of 114 patients with 
preexisting renal failure (serum creatinine .2 mg/dL) 
undergoing coronary interventions, prophylactic hemofil-
tration (fluid replacement rate 1000 mL/hour without weight 
loss), before and after percutaneous coronary intervention, 
was compared with hydration alone. Patients assigned to 
hemofiltration had significantly lower rates of CIN (5% 
versus 50%, P , 0.001), temporary renal replacement 
therapy (3% versus 25%, P , 0.001), inhospital mortality 
(2% versus 14%, P = 0.02), and one-year mortality (10% 
versus 30, P = 0.01).148 Another randomized study from 
the same institution further showed that meticulous hydra-
tion combined with hemofiltration both before and after 
exposure to contrast media versus hemofiltration only after 
exposure to contrast versus hydration alone was associated 
with a lower incidence of CIN (3% versus 26% versus 40%, 
respectively, P = 0.03), requirement for hemodialysis (0% 
versus 10% and 30%, P = 0.002) and inhospital mortality 
(0% versus 10% versus 20%, P = 0.03).149
Targeted renal therapy
Targeted renal therapy is an approach aimed at delivering 
therapeutic agents directly to the kidneys using a dedicated 
Benephit™ (FlowMedica, Fremont, CA) infusion system. This 
approach provides elevated and sustained concentrations of 
drugs in the kidneys while minimizing systemic exposure and 
side effects. In a study of 285 patients at risk for CIN, the 
actual observed rate of CIN using the infusion of fenoldo-
pam directly into renal arteries was significantly lower than 
predicted by risk score calculations (8.1% actual CIN versus 
28.0% predicted; P , 0.0001).56,150
Conclusion
CIN is an iatrogenic disorder, resulting from physician-
directed administration of contrast media. It is a prevalent 
condition in patients at risk and is associated with an 
adverse prognosis. To date, no strategy has been shown 
to prevent CIN effectively beyond meticulous patient 
selection with careful risk/benefit analysis, adequate 
intravenous periprocedural hydration with isotonic saline, 
and minimizing the amount of contrast agent. While there 
is no absolutely harmless contrast medium, low osmolar 
or iso-osmolar contrast agents have a superior safety 
profile with regard to nephrotoxicity as compared with 
high osmolar agents, and are at present recommended by 
the current guidelines.101 All patients with chronic kidney 
disease undergoing contrast exposure should receive 
preventive hydration with isotonic saline, to be started at 
least 12 hours before angiography and continued for at 
least 24 hours afterwards. Repeated exposure to contrast 
media, within a short time period (3–10 days) should 
be discouraged whenever possible. Medications known 
to worsen renal function should be withheld for at least 
48 hours preprocedure. Hypotension should be recognized 
and treated promptly. Prophylactic hemofiltration six hours 
before complex procedures may be considered in very 
high-risk patients, although further studies of this invasive 
modality are needed. Novel therapies, such as controlled 
hydration combined with forced diuresis, have shown 
promising initial results, but more data are needed before 
adopting this modality for CIN prevention.
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